Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Working Capital Changes: 2022-2025

Historic Other Working Capital Changes for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$1.4 million.

  • Phathom Pharmaceuticals' Other Working Capital Changes fell 168.21% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.8 million, marking a year-over-year decrease of 185.87%. This contributed to the annual value of $7.7 million for FY2024, which is 4.90% down from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Other Working Capital Changes is -$1.4 million, which was down 189.00% from $1.6 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Other Working Capital Changes' 5-year high stood at $5.9 million during Q4 2024, with a 5-year trough of -$7.8 million in Q1 2025.
  • In the last 3 years, Phathom Pharmaceuticals' Other Working Capital Changes had a median value of $254,000 in 2023 and averaged $736,455.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first surged by 2,218.11% in 2024, then plummeted by 1,647.20% in 2025.
  • Phathom Pharmaceuticals' Other Working Capital Changes (Quarterly) stood at $4.2 million in 2022, then crashed by 93.88% to $254,000 in 2023, then skyrocketed by 2,218.11% to $5.9 million in 2024, then tumbled by 168.21% to -$1.4 million in 2025.
  • Its Other Working Capital Changes was -$1.4 million in Q3 2025, compared to $1.6 million in Q2 2025 and -$7.8 million in Q1 2025.